Tagged with partner

Global The UHC2030 Private Sector Constituency (UHC2030 PSC), which is hosted by the World Bank Group, has released a statement on the private sector commitments toward universal health coverage (UHC), ahead of Multi-stakeholder Hearings on UHC that will take place in New York on 9th May 2023. The IFPMA’s Thomas Cueni…

LatAm Axios International has been designing and implementing access to healthcare solutions in collaboration with the pharmaceutical industry and other healthcare players across Latin America (LatAm), Europe, the Middle East, Africa, and Asia for over 25 years. Managing Partner Roshel Jayasundera outlines some of the key access challenges in LatAm today,…

LatAm Sarah Aiosa oversees the entire Latin America region for MSD, where the global giant is looking to build on its 100-year legacy by better addressing the continent’s health inequities and unmet medical needs. Aiosa describes the myriad public-private partnerships that the firm has struck in LatAm across areas including cancer…

Egypt Bristol Myers Squibb’s Oscar Delgado outlines the firm’s successes in bringing innovative medicines to the Middle East and Africa in recent years, how its strategy plays out in an economically diverse region, why partnerships are of vital importance, and the ways in which BMS is participating in Egypt’s healthcare transformation.…

Europe Pierre Meulien, Executive Director- Innovative Health Initiative, presents the public-private joint undertaking that boasts a total budget of EUR 2.4 billion and aims to build on the work of the Innovative Medicines Initiative to boost collaboration between the European pharmaceutical and related industries and the European Commission.   The Innovative…

Global Drawing on the findings of EY’s recently published life sciences M&A firepower report, EY Global Life Sciences Deals Leader Subin Baral makes the case for big biopharmas to seek out alliances and partnerships as an alternative to M&A and lists ten considerations that these firms should bear in mind if…

Global Speaking from Ipsen’s US headquarters in Cambridge, Massachusetts off the back of a whirlwind first 16 months as the firm’s Chief Business Officer, Philippe-Lopes Fernandes outlines his deal-making philosophy, how the iconic French mid-cap represents a reliable partner for innovative biotechs looking to establish a global reach for their programs,…

Taiwan Charles Chen of Taiwanese firm Medigen Vaccines Biologics Corp (MVC) shares his career journey, the company’s COVID-19 vaccine strategy, and what MVC’s competitive advantages are. At MVC we have chosen a tried and tested technology platform as novel vaccine technologies face novel challenges Charles, could you start by introducing Medigen…

China PharmaBoardroom had the pleasure of interviewing HitGen chairman & CEO Dr Jin LI in July regarding the company’s focus on DNA-encoded chemical libraries (DEL) and their multipronged business strategy. Established in 2012, the company introduced the novel DEL technology platform to China.   As Dr Li recounted, “it was not…

Europe Dr Pierre Meulien, executive director of the Innovative Medicines Initiative (IMI), the world’s largest life science public-private partnership between the European Union and the European pharmaceutical industry, shares the incredible work IMI has been doing through the COVID-19 pandemic, along with the critical importance of public-private partnerships for areas like…

China Since the Chinese biopharma boom started in the late-2000s, Chinese biotechs have seen in-licensing as a shortcut to establishing their own portfolios and developing clinical development capabilities, kickstarting their growth. With most of the founding teams having returned from extensive careers in the US and the unparalleled innovation potential of…

China The partnership between global pharma giant Eli Lilly and Chinese biotech Innovent Biologics, first initiated in March 2015, continues to bear dividends for both parties. The recent announcement that Lillly has struck a deal for the exclusive license of Innovent’s TYVYT® drug outside of China stands to catapult the Chinese…